Gold nanoparticles have many uses in drug delivery and diagnostics, but a precious metal even at the nanoscale can cost a lot to manufacture and scale up for use in research and, ultimately, biomedicine. Researchers have found, though, that a type of rust particle could have the properties needed and come at a much lower price.
A group of researchers from the Salk Institute, joined by scientists from academic and industry collaborators, has demonstrated that an acetyl-CoA carboxylase, or ACC, inhibitor can shrink tumors when delivered to lung cancer cells. The inhibitor targets fat synthesis, essentially cutting off one of the tumor’s sources of growth.
Among the recommendations made to the National Cancer Advisory Board, the panel included new technologies such as drug delivery devices, advanced imaging techniques, protein studies and tumor resistance research.
Irish drugmaker Endo Pharmaceuticals has pulled away from its aim to label pain drug Opana ER as abuse-deterrent. This was a matter of concern for crush-proof tablet developer Grunenthal, which provided Endo with its technology and this week insists it is still beneficial.
Several companies in the generic topical patch space have chimed in on a May draft guidance from the FDA that was meant to make data on those patches’ adhesion properties easier to use. And they feel the administration fell short.
Australian researchers have shown that a fat-based transport system can help oral drugs reach the bloodstream through the lymphatic system, bypassing the liver where they would normally have been broken down prematurely.